A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions

Uterine Fibroids

Interventions

DRUG

Leuprorelin (GF)

Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.

DRUG

Leuprorelin (GC)

Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.